Fulgent Genetics Inc $ 11.03 0 (0%)
Volume:
46,846
Avg Vol (1m):
87,880
Market Cap $:
203.90 Mil
Enterprise Value $:
179.69 Mil
P/E (TTM):
0.00
P/B:
4.10
| Net Current Asset Value | ||
| Tangible Book | ||
| Median P/S Value | ||
|
Price: $11.03 | ||
Manual of Stocks™ Web
Financial Strength | 7.8/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Cash-To-Debt | 9.69 | ||
| Equity-to-Asset | 0.91 | ||
| Debt-to-Equity | 0.05 | ||
| Debt-to-EBITDA | -2.19 | ||
| Piotroski F-Score | 5 | ||
| Altman Z-Score | 22.57 | ||
| Beneish M-Score | -3.04 | ||
| WACC vs ROIC | |||
Profitability | 2/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Operating Margin % | -13.56 | ||
| Net Margin % | -16.84 | ||
| ROE % | -8.21 | ||
| ROA % | -7.64 | ||
| ROC (Joel Greenblatt) % | -27.11 | ||
| 3-Year Revenue Growth Rate | 16.6 | ||
| 3-Year EBITDA Growth Rate | 22.5 | ||
| 3-Year EPS without NRI Growth Rate | 0.7 |
Ratios |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Forward PE Ratio | 39.22 | ||
| PB Ratio | 4.1 | ||
| PS Ratio | 8.1 | ||
| Price-to-Free-Cash-Flow | 344.68 | ||
| Price-to-Operating-Cash-Flow | 84.85 | ||
| EV-to-EBIT | -52.79 | ||
| EV-to-EBITDA | -141.24 | ||
| EV-to-Revenue | 7.17 | ||
| Current Ratio | 11.96 | ||
| Quick Ratio | 11.96 | ||
| Days Sales Outstanding | 80.63 | ||
| Days Payable | 35.83 |
Dividend & Buy Back |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -12.1 |
Valuation & Return |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Price-to-Tangible-Book | 4.1 | ||
| Price-to-Median-PS-Value | 1.8 | ||
| Earnings Yield (Greenblatt) % | -1.88 |